Navigation Links
Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
Date:2/26/2008

-free survival, confirmed response rate, duration of response, disease control rate and safety.

The Phase 3 NSCLC monotherapy trial will be conducted concurrently with the pivotal Phase 3 first-line combination with chemotherapy NSCLC trial. Both studies will be conducted at many of the same sites and in partnership with the same global contract research organization (CRO). The first-line Phase 3 trial is also supported by a positive double-blind, placebo-controlled Phase 2 trial. For the first-line indication, Agennix has been granted a Special Protocol Assessment and Fast Track designation from the FDA, and has received favorable Scientific Advice from the EMEA. Both Phase 3 studies are expected to be active and recruiting in mid-2008.

FDA Fast Track Designation and EMEA Favorable Scientific Advice

Agennix received Fast Track designation from the FDA for the clinical development of talactoferrin as a single-agent in patients with locally advanced or metastatic NSCLC who have failed at least two prior systemic anti- cancer therapies. The Company had previously received Fast Track designation for first-line treatment of NSCLC in combination with chemotherapy.

Fast Track designation is a process designed to facilitate the development and expedite the review of drugs that treat serious diseases and address unmet medical needs. The NSCLC monotherapy Fast Track designation was granted based on positive, randomized, placebo-controlled Phase 2 results with oral talactoferrin, and the planned Phase 3 pivotal trial.

"We are very pleased that the FDA recognizes that our lead product, talactoferrin alfa, also has potential as a single-agent treatment for patients with NSCLC who have failed previous therapies and who currently have very few options," said Dr. Rajesh Malik, Chief Medical Officer of Agennix.

Agennix also received Scientific Advice from the EMEA indicating that the planned single pivotal Phase 3 global trial with talactof
'/>"/>

SOURCE Agennix
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
2. TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
3. New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
4. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
5. Experimental Drug Ketasyn(TM) Improves Memory in Age-Associated Memory Impairment Study
6. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
7. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
8. Outcomes Vary for Prostate Cancer Patients Choosing Surgery; Overall, No Treatment Proven Superior
9. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
10. Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients
11. IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... 2014 PDL BioPharma, Inc. (PDL) (NASDAQ: ... the September 12, 2014, regular quarterly dividend payment of $0.15 ... as of September 5, 2014, the record date. ... a portfolio of patents and royalty assets, consisting primarily ... license agreements with various biotechnology and pharmaceutical companies. PDL ...
(Date:9/15/2014)... Ill. , Sept. 15, 2014 ... equipment and information systems technology, announced today an ... This agreement is for Sysmex reagents, controls and ... pocH-100 i ™ , Sysmex XP-300™, XT-Series ... The agreement is effective immediately and continues until ...
(Date:9/15/2014)... VEGAS , Sept. 15, 2014  Dr. Navneet ... Las Vegas have recently announced their continued investment in cutting ... of patients treated at the Center and a national reputation ... paying off. In speaking with multiple cancer survivors who have ... is beloved for both his warm, friendly manner and his ...
Breaking Medicine Technology:PDL BioPharma Completes Regular Quarterly Dividend Payment 2Sysmex America, Inc. Renews LABSCO Distributorship 2Sysmex America, Inc. Renews LABSCO Distributorship 3Cancer Care Center Emphasizing Innovative Oncology Treatments 2
... THOUSAND OAKS, Calif., Sept. 14 Amgen (Nasdaq: ... Bank of America Merrill Lynch Global Healthcare Conference ... at 9:50 a.m. Greenwich Mean Time.  Amgen executives ... Willard Dere, M.D., senior vice president, International Chief ...
... Sept. 14 Praxis EMR has submitted its application to ... apply for HITECH certification in the country. Under the ARRA ... incentives if they can demonstrate "meaningful use" of a certified ... Department of Health and Human Services to test and certify ...
Cached Medicine Technology:Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference 2Praxis EMR Among First to Apply for HITECH Certification 2
(Date:9/16/2014)... (PRWEB) September 16, 2014 Magpi, a ... and communication applications, today announced that CEO and ... Count, a cross-sector ideation session focusing on the use ... in New York City on September 23. Dr. Selanikio ... data to provide insights on global health programming and ...
(Date:9/16/2014)... A recent article discusses the ... filler, “Expression”, which has not been approved for cosmetic ... be used as an intra-nasal splint following rhinoplasty, and ... a dermal filler. Because of its low cost, some ... and patients have had bad reactions to it including ...
(Date:9/16/2014)... Oakland, CA (PRWEB) September 16, 2014 ... double-issue journal on cancer and genetics in Cuba. ... and genetics, the two themes are intrinsically connected, since ... cancer-related articles relate to the full spectrum of cancer ... Cubans' shared ancestry is the topic of an ...
(Date:9/16/2014)... NY (PRWEB) September 16, 2014 On ... Champion Danielle Strassle at the 2014 Buffalo Bills Alumni ... Buffalo, NY. , Bills legend and NFL Hall-of-Famer ... assisted the foundation in honoring Strassle for her dedication ... professional goals and inspire others in her community to ...
(Date:9/16/2014)... Online retailer Kettlebell Kings has announced that ... kettlebell purchases in their online store. The company wants ... with this effective workout method that is quickly gaining ... carries a variety of kettlebell brands as well as ... , “We’ve seen for ourselves how effective kettlebells ...
Breaking Medicine News(10 mins):Health News:Magpi CEO and Co-founder Dr. Joel Selanikio to Speak at Health Workers Count, Global Health Session Held during the UN General Assembly 2Health News:FDA Warns Against Non-approved Dermal Filler 2Health News:FDA Warns Against Non-approved Dermal Filler 3Health News:MEDICC Review Journal Dedicates Double Issue to Cancer and Genetics 2Health News:MEDICC Review Journal Dedicates Double Issue to Cancer and Genetics 3Health News:The HearStrong Foundation and the Buffalo Bills Alumni Foundation Celebrated HearStrong Champion During 2014 Alumni Weekend 2Health News:Join the Kettlebell Movement - Kettlebell Kings Announces $0 Shipping on all Orders 2
... French . Robot-assisted surgery dramatically improves outcomes ... researchers at the Jewish General Hospital,s Lady Davis Institute ... post-operative complications and shorter hospital stays, robotic procedures also ... late 2010 in a series of studies in ...
... , WEDNESDAY, Jan. 12 (HealthDay News) -- People who have ... after receiving the results, whether they are positive or negative, ... or get screening tests that might modify that risk, despite ... in the Jan. 13 issue of the New England ...
... of Science (AAAS) has elevated four Dartmouth professors to the ... Dartmouth Medical School. Medical School faculty members Charles ... MD, join Dartmouth biologist C. Robertson McClung among the 504 ... eight other Dartmouth researchers to have earned the distinction. ...
... Jan. 12 (HealthDay News) -- Research in rats suggests that ... by persistent ringing or other noises in the ears. ... a result of hearing loss. In this study, U.S. ... variety of sound tones over an extended period of time. ...
... cancer with a relatively high degree of accuracy when applied ... cancer, according to a study in the January issue of ... was performed at the University of Washington and Seattle Cancer ... with 592 patients who were recently diagnosed with breast cancer ...
... Scientists are reporting a scientific basis for the long-standing belief ... other countries can prevent and treat cataracts, a clouding of ... of vision loss worldwide. Their study appears in Inorganic ... Wu, Fu-Yung Huang, Shih-Hsiung Wu and colleagues note that eye ...
Cached Medicine News:Health News:Robotic surgery of 'tremendous benefit' to patients, say JGH researchers 2Health News:Consumer Genetic Testing May Not Boost Users' Anxiety 2Health News:Consumer Genetic Testing May Not Boost Users' Anxiety 3Health News:Dartmouth Medical School faculty named fellows of the American Association for the Advancement of Science 2Health News:Animal Study Finds Nerve Stimulation May Thwart Tinnitus 2
The original battery-operated suction and irrigation system features a new ergonomic hand piece and superior performance characteristics that have increased the overall flow rate....
... Bringing together the best of both ... intraocular instrument is the latest addition ... lightweight Eraser bipolar cautery instruments for ... hemostasis with extrusion aspiration and backflush ...
...
...
Medicine Products: